Bioventus Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.11
- Today's High:
- $3.22
- Open Price:
- $3.15
- 52W Low:
- $0.8
- 52W High:
- $9.895
- Prev. Close:
- $3.19
- Volume:
- 124644
Company Statistics
- Market Cap.:
- $168.71 million
- Book Value:
- 3.016
- Revenue TTM:
- $513.89 million
- Operating Margin TTM:
- -7.95%
- Gross Profit TTM:
- $302.71 million
- Profit Margin:
- -55.77%
- Return on Assets TTM:
- -2.45%
- Return on Equity TTM:
- -78.45%
Company Profile
Bioventus Inc had its IPO on 2021-02-11 under the ticker symbol BVS.
The company operates in the Healthcare sector and Medical Devices industry. Bioventus Inc has a staff strength of 1,040 employees.
Stock update
Shares of Bioventus Inc opened at $3.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.11 - $3.22, and closed at $3.13.
This is a -1.88% slip from the previous day's closing price.
A total volume of 124,644 shares were traded at the close of the day’s session.
In the last one week, shares of Bioventus Inc have slipped by -10.83%.
Bioventus Inc's Key Ratios
Bioventus Inc has a market cap of $168.71 million, indicating a price to book ratio of 0.5841 and a price to sales ratio of 0.3129.
In the last 12-months Bioventus Inc’s revenue was $513.89 million with a gross profit of $302.71 million and an EBITDA of $29.94 million. The EBITDA ratio measures Bioventus Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bioventus Inc’s operating margin was -7.95% while its return on assets stood at -2.45% with a return of equity of -78.45%.
In Q1, Bioventus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1.5%.
Bioventus Inc’s PE and PEG Ratio
- Forward PE
- 12.285
- Trailing PE
- 0
- PEG
- 2.1421
Its diluted EPS in the last 12-months stands at $-4.04 per share while it has a forward price to earnings multiple of 12.285 and a PEG multiple of 2.1421. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bioventus Inc’s profitability.
Bioventus Inc stock is trading at a EV to sales ratio of 1.0642 and a EV to EBITDA ratio of -3.6275. Its price to sales ratio in the trailing 12-months stood at 0.3129.
Bioventus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $887.40 million
- Total Liabilities
- $196.06 million
- Operating Cash Flow
- $-15066000.00
- Capital Expenditure
- $3.56 million
- Dividend Payout Ratio
- 0%
Bioventus Inc ended 2024 with $887.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $887.40 million while shareholder equity stood at $188.51 million.
Bioventus Inc ended 2024 with $0 in deferred long-term liabilities, $196.06 million in other current liabilities, 79000.00 in common stock, $-304456000.00 in retained earnings and $7.46 million in goodwill. Its cash balance stood at $47.10 million and cash and short-term investments were $47.10 million. The company’s total short-term debt was $41,320,000 while long-term debt stood at $404.27 million.
Bioventus Inc’s total current assets stands at $308.66 million while long-term investments were $2.62 million and short-term investments were $0. Its net receivables were $118.54 million compared to accounts payable of $32.83 million and inventory worth $87.95 million.
In 2024, Bioventus Inc's operating cash flow was $-15066000.00 while its capital expenditure stood at $3.56 million.
Comparatively, Bioventus Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.13
- 52-Week High
- $9.895
- 52-Week Low
- $0.8
- Analyst Target Price
- $2.5
Bioventus Inc stock is currently trading at $3.13 per share. It touched a 52-week high of $9.895 and a 52-week low of $9.895. Analysts tracking the stock have a 12-month average target price of $2.5.
Its 50-day moving average was $3.63 and 200-day moving average was $2.41 The short ratio stood at 13.76 indicating a short percent outstanding of 0%.
Around 1563% of the company’s stock are held by insiders while 6472.1% are held by institutions.
Frequently Asked Questions About Bioventus Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company’s restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.